近7天获得连续资金净流入，科创医药ETF嘉实(588700)规模创近3月新高！机构：坚定看好创新药出海

Group 1 - The core viewpoint highlights the rising trend of innovative pharmaceuticals in China, indicating that the industry is in the early stages of realizing innovation results, with significant opportunities for independent development and large-scale transactions in the future [2][3] - The liquidity of the Kexin Pharmaceutical ETF managed by Jiashi is strong, with a turnover rate of 29.7% and a trading volume of 86.71 million yuan, making it the most actively traded among comparable funds [2] - The Kexin Pharmaceutical ETF managed by Jiashi has reached a new high in scale at 291 million yuan and a new high in shares at 235 million, both ranking first among comparable funds [2] Group 2 - Recent reports from Zhongtai Securities indicate that several leading companies in the innovative drug industry have announced positive half-year results, and many established pharmaceutical companies are implementing buyback plans, reflecting confidence in the sector [3] - The top ten weighted stocks in the Shanghai Stock Exchange STAR Market Biomedicine Index account for 49.14% of the index, with companies like United Imaging Healthcare and BeiGene leading the list [3][5] - Investors without stock accounts can access opportunities in the STAR Market biopharmaceutical sector through the Kexin Pharmaceutical ETF Jiashi linked fund [5]